Literature DB >> 7629129

Two distinct signaling pathways activate the latent DNA binding function of p53 in a casein kinase II-independent manner.

T R Hupp1, D P Lane.   

Abstract

Post-translational modification of a carboxyl-terminal negative regulatory domain in vitro by either casein kinase II or protein kinase C allosterically activates the latent sequence-specific DNA binding function of p53. Reported here is a biochemical approach to determine the types of signaling pathways and enzymes that are involved in p53 activation in cells. Using a novel chromatographic method, we have been able to separate three distinct biochemical forms of p53 that have been synthesized in vivo; two are in an activated state, and one is in a latent state for sequence-specific DNA binding. The two activated forms of p53 appear to be controlled individually by either a constitutive or a UV-inducible signaling pathway. p53 lacking the COOH-terminal casein kinase II site (p53 delta 4) was characterized biochemically and used to determine the affects of deletion of the casein kinase II motif on the production of the two activated forms of p53 in vivo. As observed with full-length p53, the production of two distinct chromatographic forms of activated p53 delta 4 occurs in vivo, indicating that p53 activation can occur through a casein kinase II-independent pathway and suggesting that two other factors are involved in activation of p53 in vivo.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7629129     DOI: 10.1074/jbc.270.30.18165

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  23 in total

Review 1.  Dial 9-1-1 for p53: mechanisms of p53 activation by cellular stress.

Authors:  M Ljungman
Journal:  Neoplasia       Date:  2000 May-Jun       Impact factor: 5.715

2.  Role of tumor suppressor p53 domains in selective binding to supercoiled DNA.

Authors:  Marie Brázdová; Jan Palecek; Dmitry I Cherny; Sabina Billová; Miroslav Fojta; Petr Pecinka; Borivoj Vojtesek; Thomas M Jovin; Emil Palecek
Journal:  Nucleic Acids Res       Date:  2002-11-15       Impact factor: 16.971

3.  The proline repeat domain of p53 binds directly to the transcriptional coactivator p300 and allosterically controls DNA-dependent acetylation of p53.

Authors:  David Dornan; Harumi Shimizu; Lindsay Burch; Amanda J Smith; Ted R Hupp
Journal:  Mol Cell Biol       Date:  2003-12       Impact factor: 4.272

4.  Activities and response to DNA damage of latent and active sequence-specific DNA binding forms of mouse p53.

Authors:  Y Wu; H Huang; Z Miner; M Kulesz-Martin
Journal:  Proc Natl Acad Sci U S A       Date:  1997-08-19       Impact factor: 11.205

5.  Regulation of p53 by metal ions and by antioxidants: dithiocarbamate down-regulates p53 DNA-binding activity by increasing the intracellular level of copper.

Authors:  G W Verhaegh; M J Richard; P Hainaut
Journal:  Mol Cell Biol       Date:  1997-10       Impact factor: 4.272

6.  E2F1 has both oncogenic and tumor-suppressive properties in a transgenic model.

Authors:  A M Pierce; R Schneider-Broussard; I B Gimenez-Conti; J L Russell; C J Conti; D G Johnson
Journal:  Mol Cell Biol       Date:  1999-09       Impact factor: 4.272

7.  DNA damage activates p53 through a phosphorylation-acetylation cascade.

Authors:  K Sakaguchi; J E Herrera; S Saito; T Miki; M Bustin; A Vassilev; C W Anderson; E Appella
Journal:  Genes Dev       Date:  1998-09-15       Impact factor: 11.361

Review 8.  Regulation of p53 by protein kinase C during multi-stage carcinogenesis.

Authors:  L Magnelli; V Chiarugi
Journal:  J Cancer Res Clin Oncol       Date:  1997       Impact factor: 4.553

Review 9.  Posttranslational phosphorylation of mutant p53 protein in tumor development.

Authors:  Manabu Matsumoto; Mutsuo Furihata; Yuji Ohtsuki
Journal:  Med Mol Morphol       Date:  2006-06       Impact factor: 2.309

10.  Differential recognition by the tumor suppressor protein p53 of DNA modified by the novel antitumor trinuclear platinum drug BBR3464 and cisplatin.

Authors:  Jana Kasparkova; Miroslav Fojta; Nicholas Farrell; Viktor Brabec
Journal:  Nucleic Acids Res       Date:  2004-10-14       Impact factor: 16.971

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.